The estimated Net Worth of Pedro Claus Juan Moller San is at least $18.9 Milione dollars as of 2 December 2020. Claus San owns over 50,000 units of Y-Mabs Therapeutics Inc stock worth over $8,058,911 and over the last 6 years he sold YMAB stock worth over $9,870,500. In addition, he makes $967,497 as Chief Executive Officer e Director at Y-Mabs Therapeutics Inc.
Claus has made over 4 trades of the Y-Mabs Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of YMAB stock worth $2,560,500 on 2 December 2020.
The largest trade he's ever made was selling 200,000 units of Y-Mabs Therapeutics Inc stock on 13 May 2020 worth over $7,310,000. On average, Claus trades about 35,394 units every 100 days since 2018. As of 2 December 2020 he still owns at least 607,303 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Claus San stock trades at the bottom of the page.
Dr. Claus Juan Moller-San Pedro M.D., Ph.D. serves as Chief Executive Officer, Director of the Company., is the Chief Executive Officer, Director of the Company. Dr. Møller has served as our Chief Executive Officer and has served as a member of our Board of Directors since June 2015. Dr. Møller was the founder of Azanta A/S, or Azanta, a Danish specialty biopharmaceutical company and its Chief Executive Officer from 2009 to 2015. In addition, Dr. Møller co-founded Genmab A/S ("Genmab"), one of the largest European biopharmaceutical companies in 1999, where he served as Executive Vice President and Chief Operating Officer until 2008. Dr. Møller has also held previous executive management positions at various biopharmaceutical companies, including Executive Vice President, Chief Medical and Chief Operating Officer of OXiGENE, Inc., and Medical Director of Synthélabo Scandinavia. Dr. Møller received his M.D. and Ph.D. degrees from the University of Copenhagen.
As the Chief Executive Officer e Director of Y-Mabs Therapeutics Inc, the total compensation of Claus Pedro at Y-Mabs Therapeutics Inc is $967,497. There are no executives at Y-Mabs Therapeutics Inc getting paid more.
Claus Pedro is 58, he's been the Chief Executive Officer e Director of Y-Mabs Therapeutics Inc since . There are 4 older and 14 younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
Pedro's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE SUITE 3350, NEW YORK, NY, 10169.
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad e Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include: